J Pediatric Infect Dis Soc. 2024 Oct 1:piae105. doi: 10.1093/jpids/piae105. Online ahead of print.
ABSTRACT
The safety of casirivimab+imdevimab (CAS+IMD) (anti-SARS-CoV-2 monoclonal antibodies [mAbs]) in pediatric outpatients with COVID-19 was evaluated in a randomized, phase 1/2/3 trial. Consistent with adults, CAS+IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.
PMID:39351798 | DOI:10.1093/jpids/piae105
